The alternative complement pathway and hemocompatibility of nanosurfaces
补体替代途径和纳米表面的血液相容性
基本信息
- 批准号:9274284
- 负责人:
- 金额:$ 34.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2020-02-29
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdverse effectsAlternative Complement PathwayAntibodiesArtificial nanoparticlesBloodBlood PlateletsBlood ProteinsCancer PatientCell membraneCell surfaceCellsChargeChemicalsChemistryClinicalCollaborationsComplementComplement 3aComplement 3bComplement 5aComplement ActivationComplement Factor HComplement InactivatorsComputational BiologyComputer SimulationCore FacilityCysteineDataDepositionDevelopmentDiseaseDose-LimitingDoxorubicinDrug Delivery SystemsDrug TargetingDrug usageEngineeringEventFluorescent DyesFutureGeneric DrugsGenetic Complementation TestGoalsHumanHypersensitivityImProvImageImmuneImmunosuppressionIndividualInflammatoryInjection of therapeutic agentLectinLeukocytesLifeLipidsLiposomesLymphocyteMediatingModelingOrganismPathway interactionsPatientsPharmaceutical PreparationsPlayProteinsReactionRoleSafetySerumSerum ProteinsSurfaceTestingTherapeuticToxic effectToxinWorkbasechemical conjugatechemotherapyclinical developmentcomplement systemcomputational chemistrydensitydesigndocetaxeleosinophilexperimental studyimprovedindividual patientinhibitor/antagonistinnovationiron oxidemonocytenanoformulationnanomaterialsnanoparticleneutrophilnoveloverexpressionpolypeptidepreclinical developmentpreventpublic health relevancetooltranslational pipelineuptakevirtual
项目摘要
DESCRIPTION (provided by applicant): While having tremendous potential as a therapeutic tool, clinical use of engineered nanoparticles has also been associated with serious safety concerns. Following systemic injection, nanoparticles interact with blood proteins causing life-threating hypersensitivity. The uptake of nanoformulations loaded with anticancer toxins by immune cells causes' severe immunosuppression and dose-limiting toxicity. Activation of complement cascade is responsible for many side effects and immune uptake of engineered nanomaterials. In the preliminary data, we demonstrate that activation of complement via the alternative pathway is responsible for the majority of uptake of iron oxide nanoparticles by neutrophils, monocytes, lymphocytes, and platelets. Despite the fact that the alternative pathway has been shown to be essential for complement activation in many types of nanoformulations, the strategies to mitigate the alternative pathway activation on nanoparticles are virtually non-existent. The novel contribution of this proposal is to develop nanosurface-conjugated complement inhibitors based on natural inhibitor proteins. These proteins have been used in the therapeutics of complement-related disorders but have never been evaluated for protecting nanosurfaces against complement. Our preliminary data strongly support the hypothesis that conjugation of the natural alternative pathway inhibitors will significantly improv hemocompatibility of nanoparticles. We established the following Specific Aims: 1) Design alternative pathway inhibitors in silico for subsequent conjugation to nanosurfaces. We will perform 3-D computer modeling of the complement factors and the inhibitor proteins on nanoparticle surface to identify candidate inhibitors and conjugation strategies; 2) determine the complement inhibition efficiency of surface conjugated inhibitors. We will overexpress the inhibitor proteins, or chemically synthesize smaller polypeptides. The inhibitors will be conjugated to various types of nanoparticles via an engineered cysteine group. We will determine the efficiency of the conjugated inhibitors as a function of the inhibitor density, linke type, nanoparticle size, and surface chemistry (charge, presence of targeting antibody and fluorescent dye). These experiments will determine the most efficient inhibitors and conjugation strategies; 3) determine the efficiency of the inhibitors in improving hemocompatibility of drug delivery nanoplatforms. We will prepare nanoplatforms loaded with chemotherapy drugs. The nanoparticles will be modified with inhibitors and tested for complement activation and immune cell uptake using blood from healthy individuals and cancer patients. The results will be highly beneficial in guiding future preclinical and clinical development of inhibitor-decorated nanoplatforms.
描述(由申请人提供):尽管作为一种治疗工具具有巨大的潜力,但工程纳米颗粒的临床使用也与严重的安全问题有关。全身注射后,纳米颗粒与血液蛋白质相互作用,导致危及生命的超敏反应。免疫细胞摄取含有抗癌毒素的纳米制剂会导致严重的免疫抑制和剂量限制毒性。补体级联的激活是导致工程纳米材料的许多副作用和免疫摄取的原因。在初步数据中,我们证明通过替代途径激活补体是中性粒细胞、单核细胞、淋巴细胞和血小板摄取氧化铁纳米颗粒的主要原因。尽管事实表明,在许多类型的纳米制剂中,替代途径对于补体激活是必不可少的,但减轻替代途径对纳米颗粒激活的策略实际上是不存在的。这一建议的新贡献是开发基于天然抑制蛋白的纳米表面偶联补体抑制剂。这些蛋白质已被用于补体相关疾病的治疗,但从未被评估为保护纳米表面免受补体的影响。我们的初步数据有力地支持了这一假设,即天然替代途径抑制剂的结合将显著改善纳米粒的血液相容性。我们确定了以下具体目标:1)在硅胶中设计替代途径抑制剂,用于随后与纳米表面的偶联。我们将对补体因子和纳米颗粒表面的抑制蛋白进行三维计算机模拟,以确定候选抑制剂和偶联策略;2)确定表面偶联抑制剂的补体抑制效率。我们将过度表达抑制蛋白,或者化学合成更小的多肽。这些抑制剂将通过工程半胱氨酸基连接到各种类型的纳米颗粒上。我们将确定结合抑制剂的效率作为抑制剂密度、Linke类型、纳米颗粒大小和表面化学(电荷、靶向抗体和荧光染料的存在)的函数。这些实验将确定最有效的抑制剂和偶联策略;3)确定抑制剂在改善药物传递纳米平台的血液相容性方面的效率。我们将准备载满化疗药物的纳米平台。这些纳米粒子将被抑制剂修饰,并使用健康人和癌症患者的血液来测试补体激活和免疫细胞摄取。这一结果将对指导未来抑制剂修饰纳米平台的临床前和临床开发具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dmitri Simberg其他文献
Dmitri Simberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dmitri Simberg', 18)}}的其他基金
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10212959 - 财政年份:2016
- 资助金额:
$ 34.39万 - 项目类别:
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10053157 - 财政年份:2016
- 资助金额:
$ 34.39万 - 项目类别:
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10653068 - 财政年份:2016
- 资助金额:
$ 34.39万 - 项目类别:
The Alternative Complement Pathway and Hemocompatibility of Nanosurfaces
纳米表面的替代补体途径和血液相容性
- 批准号:
10451701 - 财政年份:2016
- 资助金额:
$ 34.39万 - 项目类别:
Painted erythrocyte carriers for therapy of acute myeloid leukemia
治疗急性髓系白血病的彩绘红细胞载体
- 批准号:
9195709 - 财政年份:2015
- 资助金额:
$ 34.39万 - 项目类别:
Non-invasive sampling of DNA markers for pancreatic cancer screening
用于胰腺癌筛查的 DNA 标记物无创采样
- 批准号:
8227305 - 财政年份:2012
- 资助金额:
$ 34.39万 - 项目类别:
Isolation of rare circulating tumor cells from blood using microbubbles
使用微泡从血液中分离罕见的循环肿瘤细胞
- 批准号:
7586521 - 财政年份:2009
- 资助金额:
$ 34.39万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 34.39万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 34.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 34.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 34.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 34.39万 - 项目类别:
Studentship














{{item.name}}会员




